- Home
- SRCE vs NVCR Comparison
SRCE vs NVCR Comparison
Compare SRCE & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRCE | NVCR |
|---|---|---|
| Founded | 1863 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SRCE | NVCR |
|---|---|---|
| Price | $62.52 | $12.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $71.25 | $28.42 |
| AVG Volume (30 Days) | 93.4K | ★ 1.6M |
| Earning Date | 01-22-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 14.53 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | $405,363,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $18.73 | $9.75 |
| Revenue Next Year | $2.28 | $5.62 |
| P/E Ratio | $10.47 | ★ N/A |
| Revenue Growth | 9.59 | ★ 11.17 |
| 52 Week Low | $52.14 | $10.70 |
| 52 Week High | $67.77 | $31.17 |
Technical Indicators
Market Signals| Indicator | SRCE | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 52.14 |
| Support Level | $65.42 | $12.30 |
| Resistance Level | $65.65 | $13.64 |
| Average True Range (ATR) | 1.28 | 0.48 |
| MACD | -0.49 | 0.02 |
| Stochastic Oscillator | 17.16 | 39.89 |
Price Performance
Historical ComparisonAbout SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.